OR WAIT null SECS
Its second fund raiser, which raised $ 8.7 million, allows Kayentis to accelerate the deployment of its team and solutions on the US market.
Kayentis, the provider of the “unique paper-based e-trial” solution, is strengthening its U.S. presence.Kayentis, a global leader of digital pen and paper technology, is strengthening its U.S. presence by hiring new staff and expanding its office space, therefore dynamically supporting its expansion in North America.
Philadelphia, PA / Gif sur Yvette, France - September 30, 2008
Its second fund raiser, which raised $ 8.7 million, allows Kayentis to accelerate the deployment of its team and solutions on the US market. Kayentis offices are conveniently located at the Philadelphia Life Sciences incubator, the Science Center, which is in close proximity to an extensive high technology and scientific community. The company’s business development and competitive strategy includes the rapid growth of its presence in the United States. This is in response to the high market demand for Kayentis’ “unique paper-based e-trial” services and will ensure local, high-quality support to clinical studies performed in North America. Clin’form®, this “unique paper-based e-trial” solution, provides the easiest data collection method possible for both patients and physicians (pen & paper) combined with all the advantages of electronic data management (accurate timestamps, audit trail functionalities, real-time access, alerts, etc.).
“Kayentis is continually and rapidly expanding its client base,” says Philippe Berna, Kayentis CEO. “Our solutions are deployed for more than 50 clinical studies in 45 countries, for international pharmaceutical laboratories, biotech and CRO. It is to answer better the growing interest in our product line in the US that we are significantly accelerating our presence there. We have hired, and are currently hiring, experienced staff both in the technical and sales fields. Being located at the Science Center in Philadelphia matches perfectly our desire to be close to the Life Science industry.”
“We are committed to provide high-level service to the North American market. Developing our presence in the US is a normal step to answer our customers’ needs and better serve them, by offering solutions which cover all their needs at each stage of the drug life cycle: R&D, Pre-Clinical, Clinical, Post-Market and Sales” adds Guillaume Juge, General Manager. “Considering our business successes and our ambitious US business plan, the Coface, on behalf of the French state, decided to support our export strategy to a total value of $ 5.8 million. It is the first time that a company of our size obtained such an amount. It is a tremendous recognition of Kayentis’ expertise in the Life Sciences area.”
The company will be showcasing its solutions from November 10-11, 2008 in Philadelphia at the Biotech 2008 event (http://www.biotech2008.org/) held by BioNJ, the New Jersey biotech association (http://www.biotechnj.org) which Kayentis is currently a member.
Kayentis is the leading provider of Digital Pen & Paper (DPP) solutions for the clinical trial industry. Built on the Forms Automation System (FAS) architecture, the Clin’Form® solution allows for all data written using a digital pen and paper, enabling Anoto functionality, to be recorded in an information system and shared via a secure web portal. This cutting-edge solution combines the ease of use of paper with the high technology tools offered by the digital world. Kayentis is HP Solution Business Partner and Anoto Platinum Partner.
To discover more about this unique solution please visit www.kayentis.com.